Saiba

Saiba Biotech is an early-stage, private Swiss biotech aiming to revolutionize healthcare by applying vaccination principles to chronic diseases. Its core technology involves virally shaped nanoparticles (VLPs) that act as highly immunogenic scaffolds to induce strong, targeted antibody responses, even in elderly populations. The company's pipeline targets significant unmet needs in areas like psoriasis, multiple sclerosis, Alzheimer's, and Parkinson's disease, positioning it at the intersection of vaccinology and chronic disease therapeutics. Leadership combines scientific expertise in immunology with financial and entrepreneurial experience.

Virus-Like Particle (VLP) conjugate vaccine platform. Uses virally shaped nanoparticles as a highly immunogenic scaffold to display target antigens, inducing strong and durable antibody responses, optimized for efficacy in elderly populations.

Saiba competes in two arenas: against large pharma and biotechs developing monoclonal antibodies and other therapies for chronic diseases (e.g., Biogen, Roche in Alzheimer's), and against other VLP and novel vaccine platform companies (e.g., SpyBiotech, VLP Therapeutics). Its differentiation lies in the specific application of its VLP platform to induce strong immune responses against self-antigens in the elderly, a niche with high barriers but potentially transformative rewards.